Hydrochlorothiazide Orifarm (Hydrochlorothiazide)

Hydrochlorothiazide Orifarm is indicated for several conditions where reduction of excess fluid or blood pressure is desired.

• Hypertension (elevated systemic arterial pressure) – helps lower blood pressure by reducing plasma volume.
• Edema associated with congestive heart failure – decreases fluid accumulation in the lungs and peripheral tissues.
• Edema due to chronic kidney disease or renal impairment – promotes urinary sodium and water loss when kidney function is compromised.
• Edema related to liver cirrhosis – assists in managing ascites and peripheral swelling caused by portal hypertension.
• Generalized fluid overload in other clinical settings – useful for reducing excess extracellular fluid in various disorders.

• Hydrochlorothiazide Orifarm acts by inhibiting the sodium‑chloride symporter in the distal convoluted tubule of the nephron. This blockade reduces reabsorption of NaCl, leading to increased delivery of sodium to the collecting duct, which promotes osmotic water loss. The resulting natriuresis and diuresis lower extracellular fluid volume, decreasing cardiac preload and peripheral vascular resistance, thereby contributing to blood pressure reduction overall.

Adverse reactions to Hydrochlorothiazide Orifarm are reported with varying frequency; they can be mild and transient or, in rare cases, severe.

Common

• Increased urination (polyuria) leading to more frequent bathroom visits.
• Low blood potassium (hypokalemia) which may cause muscle fatigue.
• Low blood sodium (hyponatremia) presenting as mild confusion.
• Dizziness or light‑headedness, especially when standing quickly.
• Muscle cramps or weakness, often in the legs.
• Headache and mild nausea during the first days of therapy.

Serious

• Severe allergic reaction (anaphylaxis, skin rash, swelling) requiring immediate medical attention.
• Significant drop in blood pressure (hypotension) that may cause fainting.
• Acute kidney injury manifested by reduced urine output or rising creatinine.
• Elevated blood sugar (hyperglycemia) in patients with diabetes or predisposition.
• Severe electrolyte disturbances (e.g., hyperuricemia leading to gout attacks).

Before starting Hydrochlorothiazide Orifarm, certain clinical considerations should be reviewed to minimize risk.

• Assess renal function; avoid use in severe impairment.
• Monitor electrolytes, especially potassium and sodium, during therapy.
• Use caution in patients with a history of gout or hyperuricemia.
• Evaluate blood glucose levels in diabetic patients, as the drug may raise glucose.
• Consider the potential for orthostatic hypotension, particularly in the elderly.
• Review concomitant medications that may affect potassium balance.
• Pregnancy and breastfeeding status should be discussed with a healthcare professional.

Hydrochlorothiazide Orifarm can interact with other medicines; awareness of these interactions helps maintain safety and effectiveness.

Avoid

• Lithium – concurrent use may increase lithium levels and toxicity.
• NSAIDs (e.g., ibuprofen, naproxen) – can reduce diuretic efficacy and impair kidney function.
• ACE inhibitors or ARBs – may potentiate potassium loss and cause severe hypotension.

Use with caution

• Antidiabetic agents – may require dose adjustment due to possible rise in blood glucose.
• Other potassium‑depleting diuretics – increase risk of hypokalemia.
• Anticoagulants (e.g., warfarin) – diuretic may alter plasma volume affecting INR.
• Corticosteroids – may enhance sodium retention counteracting the diuretic effect.
• Digitalis glycosides – may increase risk of arrhythmia when electrolyte disturbances occur.